What are the appropriate indications, dosing regimens, and monitoring recommendations for dexamethasone use in pediatric patients?

Dexamethasone in Pediatrics

For bacterial meningitis in children ≥6 weeks old with H. influenzae type b, dexamethasone 0.15 mg/kg every 6 hours for 2-4 days should be initiated 10-20 minutes before or with the first antibiotic dose to reduce hearing loss and neurologic sequelae. 1

Bacterial Meningitis

Indications and Dosing

Strongly recommended for:

• H. influenzae type b meningitis in infants and children ≥6 weeks old 2
  • Dose: 0.15 mg/kg every 6 hours for 2-4 days
  • Timing: Must start 10-20 minutes before or concurrent with first antibiotic dose
  • Critical caveat: Do NOT give if antibiotics already started—no benefit and potentially harmful 2

Controversial for:

• Pneumococcal meningitis in children: Evidence is mixed 2
  • May consider after weighing risks/benefits in children ≥6 weeks
  • More recent 2016 ESCMID guidelines support use in high-income countries with good medical care 1
  • Reduces hearing loss and neurologic sequelae but not mortality 1

NOT recommended for:

• Neonates (evidence insufficient and potentially harmful) 1
• Meningococcal meningitis (safe but no proven benefit) 1

Timing Window

If antibiotics already started, dexamethasone can still be initiated up to 4 hours after antibiotics, though earlier is better 1. Stop dexamethasone if bacterial meningitis is ruled out or if pathogen is neither H. influenzae nor S. pneumoniae 1.

---

Chemotherapy-Induced Nausea/Vomiting

High Emetogenic Risk Chemotherapy

Three-drug regimen: 5-HT3 antagonist + dexamethasone + aprepitant 3

If aprepitant unavailable: 5-HT3 antagonist + dexamethasone 3

If dexamethasone contraindicated: Palonosetron + aprepitant 3

Moderate Emetogenic Risk Chemotherapy

Two-drug regimen: 5-HT3 antagonist + dexamethasone 3

If dexamethasone unavailable: 5-HT3 antagonist + aprepitant (weaker recommendation) 3

Specific Contraindications

Do NOT use dexamethasone in:

• Chimeric antigen receptor T-cell (CAR-T) therapy patients 4
• Known active fungal infections 4

Benefits outweigh risks in:

• Bone tumors, germ cell tumors, hepatoblastoma, retinoblastoma, rhabdomyosarcoma 4
• Autologous hematopoietic stem cell transplant 4

---

Asthma Exacerbations

Single dose of dexamethasone 0.6 mg/kg (maximum 16 mg) is equivalent to 5 days of prednisolone for acute asthma exacerbations discharged from emergency department 5, 6

• One dose appears sufficient—two doses show no additional benefit 6
• Alternative: 0.3 mg/kg single dose may be equally effective (lower certainty evidence) 5
• Prednisolone alternatives: 1-2 mg/kg/day for 3-5 days 5

---

Croup

Dexamethasone 0.15 mg/kg (low dose) appears equivalent to 0.6 mg/kg (high dose) for mild-to-moderate croup, though evidence remains underpowered 7

• Single oral dose of 0.15-0.6 mg/kg
• Do NOT extrapolate to severe croup (baseline score >5)—insufficient evidence 7
• Both doses show similar outcomes for hospital admission, return visits, and need for racemic epinephrine 7

---

General Dosing Principles (FDA Label)

Standard pediatric dosing range: 0.02-0.3 mg/kg/day divided into 3-4 doses 8

Condition-specific dosing:

• Cerebral edema: 10 mg IV initially, then 4 mg every 6 hours IM (adult dosing; pediatric dosing not well-established) 8
• Acute allergic disorders: 4-8 mg IM first day, then oral taper 8

Critical monitoring:

• Individualize based on disease severity and patient response 8
• Taper gradually if used >few days 8
• Use preservative-free solutions in neonates, especially premature infants 8

---

Key Pitfalls to Avoid

1. Never give dexamethasone for meningitis after antibiotics started—no benefit 2
2. Do not use in neonatal meningitis—insufficient evidence and potential harm 1
3. Avoid in CAR-T therapy and active fungal infections when used as antiemetic 4
4. Do not assume higher doses are better—0.15 mg/kg often equivalent to 0.6 mg/kg for croup 7
5. Monitor blood glucose—transient hyperglycemia common but clinically insignificant at standard doses 9
6. Risk of tumor lysis syndrome in hematological malignancies 9